search results for: Martin Shkreli

All the new drugs ap­proved in 2023: Alzheimer's and gene ther­a­py cap a five-year high

3 months ago
FDA+

Nos­trum agrees to $50M set­tle­ment with DOJ over al­le­ga­tions of un­der­pay­ing Med­ic­aid

5 months ago
Pharma
Law

Tra­vere Ther­a­peu­tics just miss­es on con­fir­ma­to­ry study for kid­ney dis­ease drug, stock plum­mets

6 months ago
R&D

FDA clears Bio­gen, Sage's pill for post­par­tum de­pres­sion; What will Roivant, Bridge­Bio do next?; EQRx be­comes ...

8 months ago
Weekly

Mar­tin Shkre­li's old com­pa­nies se­cure $650,000 deal to sell Dara­prim amid bank­rupt­cy

8 months ago
Deals
Pharma

Hu­mani­gen warns of bank­rupt­cy af­ter fail­ing to bounce back from Covid-19 EUA re­jec­tion 

8 months ago
R&D
Pharma

$1 Dara­prim? Im­prim­is­Rx fa­cil­i­ty in New Jer­sey hit with FDA warn­ing let­ter

10 months ago
Pharma
FDA+

FDA ad­vi­sors back Sarep­ta's gene ther­a­py; Lay­offs, big and small; Gilead, So­bi fu­el M&A fire; End­points 100; and more

11 months ago
Weekly

‘Phar­ma Bro’ Mar­tin Shkre­li's com­pa­nies file for bank­rupt­cy

11 months ago
Pharma
Law

Chi­nook de­lays topline kid­ney con­di­tion da­ta; Elu­minex ropes in $40M+ in a Se­ries B

Last year
News Briefing

FDA clears Tra­vere’s rare kid­ney dis­ease drug, will come with REMS pro­gram

Last year
Pharma
FDA+

#JPM23: What's re­al­ly dri­ving the cost of health­care and drugs in 2023?

Last year

An Alzheimer’s re­jec­tion; Our #JPM23 dis­patch­es; Count Mod­er­na in for RSV; Biotech lay­offs per­sist; and more

Last year
Weekly

Mar­tin Shkre­li is back in the crosshairs of the fed­er­al gov­ern­ment for not stay­ing out of phar­ma

Last year
Pharma
Law

Phar­ma foe Bernie Sanders to take over lead­er­ship of Sen­ate health com­mit­tee

Last year
Pharma
Law

A Chica­go biotech skips the IPO in fa­vor of late-stage Se­ries D for a PhI­II Tourette drug

Last year
Financing
Startups

BIO in tu­mult as CEO abrupt­ly ex­its; Some good PhI­II news; Da­ta is­sues still plague No­var­tis' gene ther­a­py; Hot ...

Last year
Weekly

FDA punts Travere's rare kid­ney dis­ease NDA for three months, re­quest­ing REMS up­date

Last year
FDA+
1234 Next page Last page

latest

Most read

Boehringer In­gel­heim touts 10-year plan as it eyes over­tak­ing Bay­er as Ger­many’s largest phar­ma

4 hours ago
Pharma

In lat­est turn to au­toim­mune ther­a­pies, Cul­li­nan nabs $280M to join lu­pus space

1 hour ago
Financing
R&D

Take­da’s new deal with Kumquat; IL-2 biotech rais­es $55M

1 hour ago
News Briefing

In­tra-Cel­lu­lar on track for an­oth­er Caply­ta la­bel ex­pan­sion af­ter pos­i­tive Ph3 de­pres­sion da­ta

1 hour ago
R&D

Mar­ket­ingRx roundup: Vi­a­tris taps for­mer Mod­er­na ex­ec for com­mer­cial chief; Mer­ck de­buts PAH ef­fort

1 hour ago
Pharma
Marketing
see latest stream
A service from the Financial Times